Year: 2026
Type: article
Abstract: Dyslipidemia is a lipid metabolism disorder characterized by altered serum lipoprotein levels, with an increase in total cholesterol. The Brazilian Society of Cardiology classifies it as one of the main risk factors for atherosclerosis and coronary artery disease, potentially leading to heart attack and cardiovascular death. The objective of this research was to provide an update on the goals and treatments for dyslipidemias as evidenced in scientific studies from the last 5 years. Data collection took place in the first half of 2026, covering the last five years, in both Portuguese, English and Spanish. The databases searched were Latin American and Caribbean Literature in Health Sciences, Scientific Electronic Library Online, and National Institutes of Medicine. Studies were organized using index cards for later analysis. The main information was compiled and presented in a table containing Author, Year of publication, Type of study, Methodology, and Final Considerations. A total of 255 documents were found using the descriptors, but after filtering by year of publication and language, the number was reduced to 36. After applying the inclusion and exclusion criteria, 7 were selected for the results analysis. This research yielded 36 articles, which were selected based on inclusion and exclusion criteria. Seven articles were then included, and these are presented in a table. The studies presented follow the pharmacological treatment recommended in the Brazilian Dyslipidemia Guideline updated in 2025, such as the use of statins, anti-PCSK9 drugs (Inclisiran, Ongericimab), and bempedoic acid.
Source: Revista fisio&terapia.
DOI: 10.69849/vcdz0h38
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7161693126